Encore Medical Inc. · NYSE:EMI
Encore Medical — IPO Roadshow (August 2026)
22 slides from Encore Medical's IPO roadshow presentation, Aug 11, 2026
Slide 1: Overview
1 Overview Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to Preliminary Prospectus dated August __, 2026 , Registration Statement No. 333 - 290244
Slide 2: Free Writing Prospectus
2 Free Writing Prospectus This Free Writing Prospectus relates to the proposed initial public offering of Encore Medical, Inc. (“Encore”, “we”, “us” or “our”). We have filed a registration statement (File No. 333 - 290244), including the preliminary prospectus contained therein, with the U.S. Securi
Slide 3: Forward-Looking Statements
3 Forward - Looking Statements This presentation contains forward - looking statements. In some cases, you can identify these forward - looking statements by words such as “may,” ”might,” ”should,” “would,” “expect,”“plan,”“anticipate,” “intend,” “believe,” “estimate, “predict,” “potential” or “cont
Slide 4: Background
4 Background □ Encore has innovative products for closing septal wall defects (holes in the heart), primarily Patent Foramen Ovale (PFO), a flap - like hole between the atrial chambers of the heart. □ A PFO can enable embolic material (clots) to backflow from the right to left chambers and potential
Slide 5: Company Highlights
5 Company Highlights Differentiated technology being sold commercially $1.5 B Stroke & 100+ B Migraine opportunity Proven device with over 8,000 implants on current generation CE - marked and approved IDE and favorable FDA Trial underway Attractive margins - OUS sales help fund daily operations Stru
Slide 6: Encore PFO Closure Device
6 Encore PFO Closure Device High closure rates Small footprint, low profile, minimal use of metal Encore believes it has a superior PFO Closure Device to reduce the risk of ischemic stroke reoccurrence Device Sizes: 20, 25, 30 and 35mm Delivery device e asy to deploy and used for both PFO and ASD
Slide 7: Encore PFO Closure Device
7 Encore PFO Closure Device Illustration of PFO procedure
Slide 8: Encore Competitive Advantage
8 Encore Competitive Advantage Conformable Ease of deployment Low profile Partially or fully retrievable Low metal mass Septal puncture friendly Simple delivery Key Points of Differentiation Encore – PFO Closure Device Abbott – Amplatzer W.L. Gore – Cardioform x x x x x x x x x x x x x Note: Abbott
Slide 9: PFO/Stroke Addressable Market (TAM)
9 PFO/Stroke Addressable Market (TAM) See appendix for citations 795,000 patients suffering strokes 692,000 Ischemic strokes 277,000 cryptogenic strokes 139,000 patients with PFO $1.5B+ market opportunity Strokes annually¹ in the U.S. 87% of these strokes are ischemic² 40% of ischemic strokes have u
Slide 10: PFO/Migraine Market
10 PFO/Migraine Market See appendix for citations 45 Million existing patients suffering migraine headache 18 Million migraine + PFO 12 Million positive responders 11 Million PFO Closures $120B+ market opportunity Migraine sufferers in US 40% of migraine patients have a PFO 68% improve on blood thin
Slide 11: Europe Sales and Marketing
11 Europe Sales and Marketing » Currently selling though 11 international distributors. » Focus is on Europe and the Middle East but expanding into central Asia and Central and South America. » Strong physician adoption despite limited marketing efforts. » Our primary commercial focus will be in the
Slide 12: PFO/Stroke Clinical Strategy
12 PFO/Stroke Clinical Strategy FDA Approved Trial Underway Management believes the Clinical Pathway has been relatively de - risked PerFOrm Pivotal Study x Prospective, multicenter, randomized clinical study x Head - to - head study comparing the Encore device to existing FDA approved PFO devices (
Slide 13: PFO/Migraine Clinical Strategy
13 PFO/Migraine Clinical Strategy FDA Trial Design Encore has the opportunity to be the first approved device for treating PFO related Migraine Headache OUS Trial x Currently conducting PFO/Migraine clinical study in Europe. x Designed to demonstrate the clinical effectiveness of our PFO device for
Slide 14: Differentiated technology with no known IP conflicts
14 Differentiated technology with no known IP conflicts Intellectual Property Expiration Date Issue Date Patent # Key Patents ** 2040 10/3/2023 11,771,411 PFO Device 2030 2/5/2013 8,366,741 Occlusion Device with Centering Arm ** 7 additional patents that help protect the technology
Slide 15: License Agreement
15 License Agreement Encore entered into an Exclusive Technology License Agreement with GB Sciences, Inc . in June 2026 • Encore receives exclusive rights to GB’s artificial intelligence (“AI”) and machine - learning - enabled technology that may be further developed into tools for analyzing clinica
Slide 16: Management Team
16 Joseph Marino President & CEO, Director ▪ 30 continuous years of CEO, Chairman, Director of Public Companies ▪ Current Chairman of Encore, Cardia, Inc., and Electro - Sensors (NASDAQ) ▪ Previous Chairman at Applied Biometrics, Inc. Biomedical Dynamics Corporation ▪ Former Department Head, Univers
Slide 17: Non-Management Board Members
17 Todd Johnson Director ▪ Chief Compliance Officer Cedar Point Capital, Board Member, Lifelens Technologies, Former Private Placement Specialist, Stifel Nicolaus, Board Observer RxFunction , Inc. 15+ years experience, fundraising professional Christopher Turnbull Director ▪ Director of Encore Medic
Slide 18: Summary Financials
18 Summary Financials FYE FYE FYE 6 Mos. 6 Mos. Statement of Operations 12/31/2023 12/31/2024 12/31/2025 6/30/2025 6/30/2026 Audited Audited Audited Unaudited Unaudited Net Sales 1,434,424$ 2,134,528$ 2,585,858$ 1,010,092$ 557,395$ ** Cost of goods sold 912,078 1,361,077 1,548,302 602,083 499,799 Gr
Slide 19: Offering Summary
19 Offering Summary $15 million (plus over - allotment) Offering Size: Common Stock Security: 3 million Shares Offered: $5.00 per share Price: 15% Over - Allotment: NYSE American – Ticker EMI Listing: 6.7 million Shares O/S before offering $6.9 million $0.5 million $2.0 million $1.8 million $1.2 mil
Slide 20: Company Highlights
20 Company Highlights Differentiated technology being sold commercially $1.5 B Stroke & 100+ B Migraine opportunity Proven device with over 8,000 implants on current generation CE - marked and approved IDE and favorable FDA Trial underway Attractive margins - OUS sales help fund daily operations Str
Slide 21: Thank you!
21 Thank you!
Slide 22: Citations
22 Citations 1) Ischemic strokes (Clots). www.stroke.org. (n.d.). https://www.stroke.org/en/about - stroke/types - of - stroke/ischemic - stroke - clots 2) U.S. Department of Health and Human Services. (2022, February 1). How many people are affected by/at risk for stroke? Eunice Kennedy Shriver Nat